NMDA receptors in clinical neurology: excitatory times ahead

Since the N-methyl-D-aspartate receptor (NMDAR) subunits were cloned less than two decades ago, a substantial amount of research has been invested into understanding their physiological function in the healthy CNS. Research has also been directed at their pathological roles in various neurological diseases, including disorders resulting from acute excitotoxic insults (eg, ischaemic stroke, traumatic brain injury), diseases due to chronic neurodegeneration (eg, Alzheimer's, Parkinson's, and Huntington's diseases and amyotrophic lateral sclerosis), disorders arising from sensitisation of neurons (eg, epilepsy, neuropathic pain), and neurodevelopmental disorders associated with NMDAR hypofunction (eg, schizophrenia). Selective NMDAR antagonists have not produced positive results in clinical trials. However, there are other NMDAR-targeted therapies used in current practice that are effective for treating some neurological disorders. In this Review, we describe the evidence for the use of these therapies and provide an overview of drugs being investigated in clinical trials. We also discuss new NMDAR-targeted strategies in clinical neurology.

[1]  John Whitehead,et al.  Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial , 2000, The Lancet.

[2]  D. Alkon,et al.  PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. , 2007, Trends in pharmacological sciences.

[3]  S. Konitsiotis,et al.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.

[4]  I. Módy,et al.  Actions of ketamine, phencyclidine and MK‐801 on NMDA receptor currents in cultured mouse hippocampal neurones. , 1991, The Journal of physiology.

[5]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[6]  C. Clarke,et al.  Amantadine in Parkinson's disease. , 2003, Lancet.

[7]  G. Hardingham,et al.  The Dichotomy of NMDA Receptor Signaling , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[8]  Rachelle Doody,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[9]  O. Devinsky,et al.  Felbamate: A Clinical Trial for Complex Partial Seizures , 1991, Epilepsia.

[10]  K. Muir.  Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. , 2006, Current opinion in pharmacology.

[11]  B. Snow,et al.  The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.

[12]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[13]  G. Wilcock,et al.  A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.

[14]  L. Schneider,et al.  Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials , 2007, The Lancet Neurology.

[15]  A. Maelicke,et al.  Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  K. Fukunaga,et al.  Nefiracetam Potentiates N-Methyl-d-aspartate (NMDA) Receptor Function via Protein Kinase C Activation and Reduces Magnesium Block of NMDA Receptor , 2007, Molecular Pharmacology.

[17]  H. Haas,et al.  Histamine potentiates N-methyl-d-aspartate responses in acutely isolated hippocampal neurons , 1993, Neuron.

[18]  Z. Kmietowicz.  NICE proposes to withdraw Alzheimer's drugs from NHS , 2005, BMJ : British Medical Journal.

[19]  Rebecca P Seal,et al.  Molecular pharmacology of glutamate transporters, EAATs and VGLUTs , 2004, Brain Research Reviews.

[20]  E. Kalso,et al.  Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. , 2003, Journal of pain and symptom management.

[21]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[22]  J. Rothstein,et al.  Excitotoxic destruction facilitates brain tumor growth , 2001, Nature Medicine.

[23]  J. Monahan,et al.  d-Cycloserine: A ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics , 1989, Neuroscience Letters.

[24]  Jon W. Johnson,et al.  Mechanism of action of memantine. , 2006, Current opinion in pharmacology.

[25]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[26]  R. Roesler,et al.  Is it time to conclude that NMDA antagonists have failed? , 2003, The Lancet Neurology.

[27]  B. Dubois,et al.  Riluzole in Huntington's disease: a 3‐year, randomized controlled study , 2007, Annals of neurology.

[28]  H. Bading,et al.  The Yin and Yang of NMDA receptor signalling , 2003, Trends in Neurosciences.

[29]  C. McDougle,et al.  A pilot study of D-cycloserine in subjects with autistic disorder. , 2004, The American journal of psychiatry.

[30]  J. Albers,et al.  Amantadine and levodopa in the treatment of Parkinson's disease , 1972, Clinical pharmacology and therapeutics.

[31]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[32]  K. Lees,et al.  Excitatory amino acid antagonists for acute stroke. , 2003, The Cochrane database of systematic reviews.

[33]  S. Shinnar,et al.  Felbamate: Consensus of current clinical experience , 2006, Epilepsy Research.

[34]  N. W. Kleckner,et al.  Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. , 1999, The Journal of pharmacology and experimental therapeutics.

[35]  P. Francis,et al.  d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain , 1991, Brain Research.

[36]  M. Debono,et al.  Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. , 1993, European journal of pharmacology.

[37]  S. Nakanishi,et al.  Molecular cloning and characterization of the rat NMDA receptor , 1991, Nature.

[38]  R. Bullock,et al.  Failure of the competitive N-methyl-d-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials , 1999 .

[39]  W. Falk,et al.  A preliminary study of D-cycloserine treatment in Alzheimer's disease. , 1998, The Journal of neuropsychiatry and clinical neurosciences.

[40]  H. Diener,et al.  Termination of Acute Stroke Studies Involving Selfotel Treatment , 1997, The Lancet.

[41]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[42]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[43]  K. Laake,et al.  D-cycloserine for Alzheimer's disease. , 2002, The Cochrane database of systematic reviews.

[44]  J. Olin,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.

[45]  T. F. Murray,et al.  High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. , 1992, Molecular pharmacology.

[46]  V. Meininger,et al.  Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[47]  G. Oxenkrug,et al.  Mitochondria as a Target for Neurotoxins and Neuroprotective Agents , 2003, Annals of the New York Academy of Sciences.

[48]  S. Bachurin,et al.  Dimebon and Tacrine Inhibit Neurotoxic Action of β-Amyloid in Culture and Block L-type Ca2+ Channels , 2001, Bulletin of Experimental Biology and Medicine.

[49]  S. Hashtroudi,et al.  d-Cycloserine enhances implicit memory in Alzheimer patients , 1996, Neurology.

[50]  Steven G Potkin,et al.  Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[51]  R. Görtelmeyer,et al.  Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. , 1992, Arzneimittel-Forschung.

[52]  P. Paoletti,et al.  The Micromolar Zinc-Binding Domain on the NMDA Receptor Subunit NR2B , 2005, The Journal of Neuroscience.

[53]  C. Ikonomidou,et al.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? , 2002, The Lancet Neurology.

[54]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[55]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[56]  C. Fehling.  THE EFFECT OF ADDING AMANTADINE TO OPTIMUM L‐DOPA DOSAGE IN PARKINSON'S SYNDROME , 1973, Acta neurologica Scandinavica.

[57]  B. Meldrum,et al.  2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—I Anticonvulsant properties , 1985, Neuropharmacology.

[58]  Huda Y. Zoghbi,et al.  The Story of Rett Syndrome: From Clinic to Neurobiology , 2007, Neuron.

[59]  M. Weller,et al.  Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.

[60]  L. Goldstein,et al.  Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. , 2001, JAMA.

[61]  S. O. Bachurin,et al.  Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons , 2003, Bulletin of Experimental Biology and Medicine.

[62]  J. Glowinski,et al.  Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action , 1994, British journal of pharmacology.

[63]  M. Rogawski,et al.  Felbamate block of recombinant N-methyl-d-aspartate receptors: selectivity for the NR2B subunit , 2000, Epilepsy Research.

[64]  J. Macdonald,et al.  Distinct Roles of Synaptic and Extrasynaptic NMDA Receptors in Excitotoxicity , 2000, The Journal of Neuroscience.

[65]  Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.

[66]  M. Johnston,et al.  Enhanced cell death in MeCP2 null cerebellar granule neurons exposed to excitotoxicity and hypoxia , 2007, Neuroscience.

[67]  S. Fahn,et al.  Long‐term evaluation of amantadine and levodopa combination in parkinsonism by double‐blind crossover analyses , 1975, Neurology.

[68]  M. Remler,et al.  Felbamate monotherapy for partial‐onset seizures , 1993, Neurology.

[69]  R. Sachdeo,et al.  Felbamate monotherapy: Controlled trial in patients with partial onset seizures , 1992, Annals of neurology.

[70]  K. Ditzler.  Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. , 1991, Arzneimittel-Forschung.

[71]  C. Clarke,et al.  Amantadine for dyskinesia in Parkinson's disease. , 2003, The Cochrane database of systematic reviews.

[72]  J. Sebolt-Leopold,et al.  Mechanisms of drug inhibition of signalling molecules , 2006, Nature.

[73]  C. Woolf,et al.  Neuronal plasticity: increasing the gain in pain. , 2000, Science.

[74]  C. Malgouris,et al.  Neuroprotective effects of riluzole on N-methyl-d-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices , 1994, Neuroscience Letters.

[75]  S. Bachurin,et al.  Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer , 2001, Annals of the New York Academy of Sciences.

[76]  M. Gobbi,et al.  Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. , 2008, European journal of pharmacology.

[77]  J. Jankovic,et al.  A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. , 2002, Parkinsonism & related disorders.

[78]  C. Parsons,et al.  Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies , 1997, Neuroscience & Biobehavioral Reviews.

[79]  P. Paoletti,et al.  Mapping the Binding Site of the Neuroprotectant Ifenprodil on NMDA Receptors , 2002, The Journal of Neuroscience.

[80]  H. Bading,et al.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.

[81]  Hoau Yan Wang,et al.  α7 Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide-induced Tau Protein Phosphorylation* , 2003, Journal of Biological Chemistry.

[82]  L. Greenfield,et al.  Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor. , 1996, Journal of Pharmacology and Experimental Therapeutics.

[83]  C. Mulle,et al.  Presynaptic glutamate receptors: physiological functions and mechanisms of action , 2008, Nature Reviews Neuroscience.

[84]  Bert Sakmann,et al.  Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes , 1992, Science.

[85]  R. Sofia,et al.  Effect of Anticonvulsant Felbamate on GABAA Receptor System , 1991, Epilepsia.

[86]  C. Wasterlain,et al.  Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. , 1993, The Journal of pharmacology and experimental therapeutics.

[87]  S. Bakchine,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. , 2008, Journal of Alzheimer's disease : JAD.

[88]  Takahiro Takano,et al.  Glutamate release promotes growth of malignant gliomas , 2001, Nature Medicine.

[89]  Wei Yang Lu,et al.  G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors , 1999, Nature Neuroscience.

[90]  L. Metman,et al.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.

[91]  M. Yamazaki,et al.  Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs , 1992, Nature.

[92]  J E Walker,et al.  A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. , 1972, Journal of chronic diseases.

[93]  J. de Vellis,et al.  Nicotinic Receptors Differentially Regulate N-Methyl-d-aspartate Damage in Acute Hippocampal Slices , 2003, Journal of Pharmacology and Experimental Therapeutics.

[94]  P. Banerjee,et al.  Comments on “Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-d-aspartate Receptors in Rat Hippocampal Neurons” , 2005, Journal of Pharmacology and Experimental Therapeutics.

[95]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[96]  S. Mennerick,et al.  Selective Depression of Low–Release Probability Excitatory Synapses by Sodium Channel Blockers , 2000, Neuron.

[97]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[98]  Herman Wolosker.  D-Serine Regulation of NMDA Receptor Activity , 2006, Science's STKE.

[99]  J. Coyle,et al.  Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. , 1999, The American journal of psychiatry.

[100]  B. Orser,et al.  In CA1 Pyramidal Neurons of the Hippocampus Protein Kinase C Regulates Calcium-Dependent Inactivation of NMDA Receptors , 2000, The Journal of Neuroscience.

[101]  P. Leigh,et al.  Riluzole and amyotrophic lateral sclerosis , 1996, The Lancet.

[102]  S. Lipton.  Pathologically activated therapeutics for neuroprotection , 2007, Nature Reviews Neuroscience.

[103]  F. Jirik,et al.  Prion protein attenuates excitotoxicity by inhibiting NMDA receptors , 2008, The Journal of cell biology.

[104]  G. Pledger,et al.  Felbamate for partial seizures , 1991, Neurology.

[105]  V. Meininger,et al.  A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis , 2002, Journal of Neurology.

[106]  T. F. Murray,et al.  Differential binding properties of [H-3]dextrorphan and [H-3]MK-801 in heterologously expressed NMDA receptors , 2022 .

[107]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[108]  Ann Marie Craig,et al.  NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo , 2007, The Journal of Neuroscience.

[109]  M. Bullock,et al.  The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. , 2005, Journal of neurotrauma.

[110]  I. Izquierdo,et al.  On the participation of hippocampal PKC in acquisition, consolidation and reconsolidation of spatial memory , 2007, Neuroscience.

[111]  W. Poewe,et al.  Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[112]  E. Waxman,et al.  N-methyl-D-aspartate Receptor Subtypes: Multiple Roles in Excitotoxicity and Neurological Disease , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[113]  E. Kalso,et al.  Perioperative ketamine for acute postoperative pain. , 2015, The Cochrane database of systematic reviews.

[114]  T. Coderre,et al.  Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. , 2000, Journal of pain and symptom management.

[115]  Michael W. Salter,et al.  Src kinases: a hub for NMDA receptor regulation , 2004, Nature Reviews Neuroscience.

[116]  A. Brown,et al.  Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain. , 1996, European journal of pharmacology.

[117]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[118]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[119]  NMDA Receptor Subunits: Function and Pharmacology , 2007 .

[120]  R. Young,et al.  Amantadine in the treatment of Parkinson's disease. , 1969, JAMA.

[121]  B. Reisberg,et al.  A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. , 2006, Archives of neurology.

[122]  P. Calabresi,et al.  Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. , 1996, The Journal of pharmacology and experimental therapeutics.

[123]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[124]  F. Savéry.  Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. , 1977, Diseases of the nervous system.

[125]  R. Sacco,et al.  Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. , 2001, JAMA.

[126]  J. Brotchie.  Nondopaminergic mechanisms in levodopa‐induced dyskinesia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[127]  J. Sackellares,et al.  Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). , 1993, The New England journal of medicine.

[128]  D. Alkon,et al.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[129]  P. Tariot,et al.  A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease , 2007, Alzheimer disease and associated disorders.

[130]  L. Schneider,et al.  Memantine for dementia. , 2006, The Cochrane database of systematic reviews.

[131]  Dwight E Bergles,et al.  Glutamate transporters bring competition to the synapse , 2004, Current Opinion in Neurobiology.

[132]  F. Barkhof,et al.  The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study , 2002, Multiple sclerosis.

[133]  J. Rho,et al.  Felbamate block of the N-methyl-D-aspartate receptor. , 1995, The Journal of pharmacology and experimental therapeutics.

[134]  J. Brotchie.  The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. , 2000, Annals of neurology.

[135]  R. Sofia,et al.  Felbamate modulates the strychnine-insensitive glycine receptor , 1995, Epilepsy Research.

[136]  C. Parsons,et al.  Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. , 2002, Current pharmaceutical design.

[137]  W. Dodson.  Felbamate in the Treatment of Lennox‐Gastaut Syndrome: Results of a 12‐Month Open‐Label Study Following a Randomized Clinical Trial , 1993, Epilepsia.

[138]  J. Tiihonen,et al.  Glutamatergic drugs for schizophrenia. , 2006, The Cochrane database of systematic reviews.